Skip to main content

An official website of the United States government

You have 2 new alerts

Transportation and Transit Services

General Information

  • Contract Opportunity Type: Special Notice (Original)
  • Original Published Date: Apr 27, 2023 12:29 pm EDT
  • Original Response Date: May 19, 2023 12:00 pm EDT
  • Inactive Policy: 15 days after response date
  • Original Inactive Date:
  • Initiative:

Classification

  • Original Set Aside: 8(a) Sole Source (FAR 19.8)
  • Product Service Code: V119 - TRANSPORTATION/TRAVEL/RELOCATION- TRANSPORTATION: OTHER
  • NAICS Code:
    • 561990 - All Other Support Services
  • Place of Performance:
    Silver Spring , MD 20993
    USA

Description

Notice of Intent Sole Source

This announcement is not a Request for Proposal.

The US Food and Drug Administration {FDA), Office of Finance Budget Acquisition and Planning, intends to award a sole source award,  in accordance with Section 8(a) of the Small Business Act (15 U.S.C. § 637(a)), and the Federal Acquisition Regulation (FAR) Part 19.8, and the executed Partnership Agreement between the U.S. Small Business Administration (SBA) and the U.S. Food and Drug Administration; under an 8(a) BUSINESS DEVELOPMENT (BD) PROGRAM - SOLE SOURCE REQUIREMENT UNDER THE EXECUTED PARTNERSHIP AGREEMENT PROGRAM -  SBA Requirement #BD1676407151H; to a current contract holder, C2 ALASKA, LLC.

The requirement is to provide transportation, transit and parking related services for the Food and Drug Administration (FDA). Services will primarily be provided on the White Oak Campus (WO), located at 20903 New Hampshire Ave, Silver Spring, Maryland 10993, and at other agency sites in the Washington, DC-Metropolitan Area.

The propose simplified acquisition is for services; the Government intends to solicit and negotiate to only one source. A determination by the Government not to compete this proposed simplified acquisition based upon responses to this notice, is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive requirement. No further solicitation is available.

FDA will consider all responses received prior to the closing date of this notice and will use responses in determining, whether it is necessary to use full and open competition for this requirement. Responses shall be emailed to Natapol Sirikhan, Natapol.Sirikhan@fda.hhs.gov, by 05/19/23, 12:00 PM EST.

Contact Information

Contracting Office Address

  • 10903 New Hampshire Avenue
  • Silver Spring , MD 20993
  • USA

Primary Point of Contact

Secondary Point of Contact





History

  • Jun 03, 2023 11:59 pm EDTSpecial Notice (Original)